Key Insights

Highlights

Treatment Research

1 treatments under study, led by Vtx2337 Plus Radiotherapy

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT01289210Phase 1/2TerminatedPrimary

VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Showing all 1 trials

Research Network

Common Treatments

  • Vtx2337 Plus Radiotherapy1

Active Sponsors

  • Celgene1
  • Stanford University1

Top Investigators

Activity Timeline